Pharmacogenomics working group (correction)
Executive Summary
GlaxoSmithKline Director-Clinical Pharmacogenetics Mark Watson, MD/PhD, is the chair of the Pharmacogenetics Working Group. "The Pink Sheet" incorrectly reported that Wyeth Senior Director-Regulatory Affairs Ronald Salerno was the chair of the pharmacogenetics working group (1"The Pink Sheet" Oct. 11, 2004, p. 13). Salerno stepped down in July. The working group is not sponsored by the Pharmaceutical Research & Manufacturers of America; it was formed from the pharmacogenetics special interest group of the Drug Information Association in 2000. PhRMA's Genomics Division, which was formed in 2002, is chaired by Millennium Pharmaceuticals Director-Regulatory Strategy & Intelligence Christopher Webster, PhD...